乳腺血管肉瘤新辅助化疗诱导病理反应的临床病理学和分子相关性

IF 3.1 2区 医学 Q2 GENETICS & HEREDITY
Hsin-Yi Chang, Josephine K. Dermawan, Maria Gabriela Kuba, Aimee M. Crago, Samuel Singer, William Tap, Ping Chi, Sandra D'Angelo, Evan Rosenbaum, Cristina R. Antonescu
{"title":"乳腺血管肉瘤新辅助化疗诱导病理反应的临床病理学和分子相关性","authors":"Hsin-Yi Chang,&nbsp;Josephine K. Dermawan,&nbsp;Maria Gabriela Kuba,&nbsp;Aimee M. Crago,&nbsp;Samuel Singer,&nbsp;William Tap,&nbsp;Ping Chi,&nbsp;Sandra D'Angelo,&nbsp;Evan Rosenbaum,&nbsp;Cristina R. Antonescu","doi":"10.1002/gcc.23240","DOIUrl":null,"url":null,"abstract":"<p>Both primary and secondary breast angiosarcoma (AS) are characterized by multifocal presentation and aggressive behavior. Despite multimodality therapy, local and distant relapse rates remain high. Therefore, neoadjuvant chemotherapy (NACT) is employed to improve the R0 resection rates and survival, but its benefits remain controversial. Herein, we investigate pathologic and molecular correlates to NACT-induced histologic response in a group of 29 breast AS, 4 primary and 25 radiation-associated (RA). The two NACT regimens applied were anthracycline- and non-anthracycline-based. The pathologic response grade was defined as: I: ≤ 50%, II: 51%–90%, III: 91%–99%, and IV: 100%. An additional 45 primary AS and 102 RA-AS treated by surgery alone were included for survival comparison. The genomic landscape was analyzed in a subset of cases and compared to a cohort of AS without NACT on a paired tumor-normal targeted DNA NGS platform. All patients were females, with a median age of 31 years in primary AS and 68 years in RA-AS. All surgical margins were negative in NACT group. The NACT response was evenly divided between poor (Grades I–II; <i>n</i> = 15) and good responders (Grades III–IV; <i>n</i> = 14). Mitotic count &gt;10/mm<sup>2</sup> was the only factor inversely associated with pathologic response. By targeted NGS, all 10 post-NACT RA-AS demonstrated <i>MYC</i> amplification, while both primary AS harbored <i>KDR</i> mutations. TMB or other genomic alterations did not correlate with pathologic response. All four patients with Grade IV response remained free of disease. The good responders had a significantly better disease-specific survival (<i>p</i> = 0.04). There was no survival difference with NACT status or the NACT regimens applied. However, NACT patients with <i>MYC</i>-amplified tumors showed better disease-free survival (<i>p</i> = 0.04) compared to <i>MYC</i>-amplified patients without NACT. The overall survival of NACT group correlated with size &gt;10 cm (<i>p</i> = 0.02), pathologic response (<i>p</i> = 0.04), and multifocality (<i>p</i> = 0.01) by univariate, while only size &gt;10 cm (<i>p</i> = 0.03) remained significant by multivariate analysis.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 5","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinicopathologic and molecular correlates to neoadjuvant chemotherapy-induced pathologic response in breast angiosarcoma\",\"authors\":\"Hsin-Yi Chang,&nbsp;Josephine K. Dermawan,&nbsp;Maria Gabriela Kuba,&nbsp;Aimee M. Crago,&nbsp;Samuel Singer,&nbsp;William Tap,&nbsp;Ping Chi,&nbsp;Sandra D'Angelo,&nbsp;Evan Rosenbaum,&nbsp;Cristina R. Antonescu\",\"doi\":\"10.1002/gcc.23240\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Both primary and secondary breast angiosarcoma (AS) are characterized by multifocal presentation and aggressive behavior. Despite multimodality therapy, local and distant relapse rates remain high. Therefore, neoadjuvant chemotherapy (NACT) is employed to improve the R0 resection rates and survival, but its benefits remain controversial. Herein, we investigate pathologic and molecular correlates to NACT-induced histologic response in a group of 29 breast AS, 4 primary and 25 radiation-associated (RA). The two NACT regimens applied were anthracycline- and non-anthracycline-based. The pathologic response grade was defined as: I: ≤ 50%, II: 51%–90%, III: 91%–99%, and IV: 100%. An additional 45 primary AS and 102 RA-AS treated by surgery alone were included for survival comparison. The genomic landscape was analyzed in a subset of cases and compared to a cohort of AS without NACT on a paired tumor-normal targeted DNA NGS platform. All patients were females, with a median age of 31 years in primary AS and 68 years in RA-AS. All surgical margins were negative in NACT group. The NACT response was evenly divided between poor (Grades I–II; <i>n</i> = 15) and good responders (Grades III–IV; <i>n</i> = 14). Mitotic count &gt;10/mm<sup>2</sup> was the only factor inversely associated with pathologic response. By targeted NGS, all 10 post-NACT RA-AS demonstrated <i>MYC</i> amplification, while both primary AS harbored <i>KDR</i> mutations. TMB or other genomic alterations did not correlate with pathologic response. All four patients with Grade IV response remained free of disease. The good responders had a significantly better disease-specific survival (<i>p</i> = 0.04). There was no survival difference with NACT status or the NACT regimens applied. However, NACT patients with <i>MYC</i>-amplified tumors showed better disease-free survival (<i>p</i> = 0.04) compared to <i>MYC</i>-amplified patients without NACT. The overall survival of NACT group correlated with size &gt;10 cm (<i>p</i> = 0.02), pathologic response (<i>p</i> = 0.04), and multifocality (<i>p</i> = 0.01) by univariate, while only size &gt;10 cm (<i>p</i> = 0.03) remained significant by multivariate analysis.</p>\",\"PeriodicalId\":12700,\"journal\":{\"name\":\"Genes, Chromosomes & Cancer\",\"volume\":\"63 5\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genes, Chromosomes & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/gcc.23240\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes, Chromosomes & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/gcc.23240","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

摘要

原发性和继发性乳腺血管肉瘤(AS)均以多灶性表现和侵袭性行为为特征。尽管采用了多模式治疗,但局部和远处复发率仍然很高。因此,新辅助化疗(NACT)被用来提高R0切除率和生存率,但其益处仍存在争议。在此,我们研究了一组 29 例乳腺 AS(4 例原发性,25 例放射相关性(RA))中 NACT 诱导组织学反应的病理学和分子相关性。应用的两种 NACT 方案分别以蒽环类和非蒽环类为基础。病理反应等级定义为I:≤50%,II:51%-90%,III:91%-99%,IV:100%。另外还纳入了45例原发性AS和102例单纯手术治疗的RA-AS进行生存率比较。在肿瘤-正常靶向 DNA NGS 平台上,分析了部分病例的基因组状况,并与没有 NACT 的 AS 患者进行了比较。所有患者均为女性,原发性 AS 的中位年龄为 31 岁,RA-AS 的中位年龄为 68 岁。NACT 组所有手术切缘均为阴性。NACT反应平均分为差(I-II级;n = 15)和好(III-IV级;n = 14)两组。有丝分裂计数>10/mm2是唯一与病理反应成反比的因素。通过靶向 NGS,所有 10 例 NACT 后 RA-AS 均显示 MYC 扩增,而两例原发性 AS 均携带 KDR 突变。TMB或其他基因组改变与病理反应无关。所有四名 IV 级反应的患者均未再发病。良好反应者的疾病特异性生存率明显更高(p = 0.04)。NACT状态或采用的NACT方案在生存率上没有差异。不过,与未接受NACT治疗的MYC扩增肿瘤患者相比,接受NACT治疗的MYC扩增肿瘤患者的无病生存率更高(p = 0.04)。单变量分析显示,NACT组的总生存期与肿瘤大小>10厘米(p = 0.02)、病理反应(p = 0.04)和多灶性(p = 0.01)相关,而多变量分析显示,只有肿瘤大小>10厘米(p = 0.03)仍具有显著性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinicopathologic and molecular correlates to neoadjuvant chemotherapy-induced pathologic response in breast angiosarcoma

Both primary and secondary breast angiosarcoma (AS) are characterized by multifocal presentation and aggressive behavior. Despite multimodality therapy, local and distant relapse rates remain high. Therefore, neoadjuvant chemotherapy (NACT) is employed to improve the R0 resection rates and survival, but its benefits remain controversial. Herein, we investigate pathologic and molecular correlates to NACT-induced histologic response in a group of 29 breast AS, 4 primary and 25 radiation-associated (RA). The two NACT regimens applied were anthracycline- and non-anthracycline-based. The pathologic response grade was defined as: I: ≤ 50%, II: 51%–90%, III: 91%–99%, and IV: 100%. An additional 45 primary AS and 102 RA-AS treated by surgery alone were included for survival comparison. The genomic landscape was analyzed in a subset of cases and compared to a cohort of AS without NACT on a paired tumor-normal targeted DNA NGS platform. All patients were females, with a median age of 31 years in primary AS and 68 years in RA-AS. All surgical margins were negative in NACT group. The NACT response was evenly divided between poor (Grades I–II; n = 15) and good responders (Grades III–IV; n = 14). Mitotic count >10/mm2 was the only factor inversely associated with pathologic response. By targeted NGS, all 10 post-NACT RA-AS demonstrated MYC amplification, while both primary AS harbored KDR mutations. TMB or other genomic alterations did not correlate with pathologic response. All four patients with Grade IV response remained free of disease. The good responders had a significantly better disease-specific survival (p = 0.04). There was no survival difference with NACT status or the NACT regimens applied. However, NACT patients with MYC-amplified tumors showed better disease-free survival (p = 0.04) compared to MYC-amplified patients without NACT. The overall survival of NACT group correlated with size >10 cm (p = 0.02), pathologic response (p = 0.04), and multifocality (p = 0.01) by univariate, while only size >10 cm (p = 0.03) remained significant by multivariate analysis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Genes, Chromosomes & Cancer
Genes, Chromosomes & Cancer 医学-遗传学
CiteScore
7.00
自引率
8.10%
发文量
94
审稿时长
4-8 weeks
期刊介绍: Genes, Chromosomes & Cancer will offer rapid publication of original full-length research articles, perspectives, reviews and letters to the editors on genetic analysis as related to the study of neoplasia. The main scope of the journal is to communicate new insights into the etiology and/or pathogenesis of neoplasia, as well as molecular and cellular findings of relevance for the management of cancer patients. While preference will be given to research utilizing analytical and functional approaches, descriptive studies and case reports will also be welcomed when they offer insights regarding basic biological mechanisms or the clinical management of neoplastic disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信